Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Trial Profile

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs BR-55 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Bracco Diagnostics
  • Most Recent Events

    • 15 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 30 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jul 2018.
    • 11 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top